| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Catumazomab |
| Brand | Removab® |
| Indication | For the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. |
| Assessment Process | |
| Rapid review commissioned | 05/08/2011 |
| Rapid review completed | 06/09/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended. |